论文部分内容阅读
大多数多发性骨髓瘤(MM)和低度恶性非霍奇金淋巴瘤(NHL)病人都有贫血表现,恶性肿瘤细胞对正常造血的损伤,自身免疫性溶血,肾脏损害和化疗引起骨髓抑制,都能导致这些类型病人贫血的发生。慢性病性贫血(ACD),其特征为骨髓红系再生不良,红细胞寿命缩短,与贫血程度有关的促红细胞生成素不足亦和这些患者的贫血有关。在过去,输血是唯一的治疗方法。重组人促红细胞生成素(rhEPO)的出现,提供了一种新的疗法。在治疗慢性肾功能衰竭和各种恶性肿瘤病人的贫血中已显示出促红细胞生成素是有效的。Ludwig等人
Most patients with multiple myeloma (MM) and low-grade non-Hodgkin’s lymphoma (NHL) have anemia, damage to normal hematopoietic cells by malignant tumor cells, autoimmune hemolysis, renal damage and chemotherapy-induced bone marrow suppression, Can lead to anemia in these types of patients. Chronic aplastic anemia (ACD), which is characterized by poor regeneration of myeloid erythroid, shorter life span of erythrocytes, lack of erythropoietin associated with anemia, is also associated with anemia in these patients. In the past, blood transfusions were the only treatment. The emergence of recombinant human erythropoietin (rhEPO) provides a new therapy. Erythropoietin has been shown to be effective in treating anemia in patients with chronic renal failure and various malignancies. Ludwig et al